RecruitingEarly Phase 1NCT05851105
the Safety and Efficacy Evaluation of HGI-002 Injection in Patients With Transfusion-Dependent α-Thalassemia
Sponsor
Shenzhen Hemogen
Enrollment
3 participants
Start Date
Oct 8, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
This is an open label study to evaluate the safety and efficacy of α-globin Restored Autologous Hematopoietic Stem Cells in α-Thalassemia Major Patients
Eligibility
Min Age: 12 YearsMax Age: 35 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a biological treatment called α-globin restored autologous hematopoietic stem cells for people with thalassemia. The study is currently recruiting participants at 1 location. People eligible for this study include aged 12 Years to 35 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALα-globin restored autologous hematopoietic stem cells
α-globin restored autologous hematopoietic stem cells modified with LentiHBA T\>C
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05851105
Related Trials
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
NCT0439862871 locations
CINC424A2X01B Rollover Protocol
NCT02386800101 locations
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
NCT06609226105 locations
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
NCT057364196 locations
A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East
NCT072159752 locations